← Browse by Condition
Medical Condition
waldenstrom macroglobulinemia
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 3
NCT05914662 Phase 2
Recruiting
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
Enrollment
42 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
NCT01804686 Phase 3
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Enrollment
700 pts
Location
United States, Argen...
Sponsor
Janssen Research & Development...